Clinical validation of an adapted Eleveld Model for high-dose propofol treatments for depression.
Burst suppression
Pharmacodynamics
Propofol
Treatment-resistant depression
Journal
Journal of clinical monitoring and computing
ISSN: 1573-2614
Titre abrégé: J Clin Monit Comput
Pays: Netherlands
ID NLM: 9806357
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
23
11
2022
accepted:
16
02
2023
medline:
27
9
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
Repeated administration of high doses of propofol to patients with treatment-resistant depression (TRD) has been shown to produce antidepressant effects in small clinical trials. These effects can be elicited when the patient's EEG burst-suppression ratio (BSR) is maintained at 70-90% for 15 min in repeated treatments. This deep anesthesia domain lies beyond the range of current propofol pharmacokinetic/pharmacodynamic (PK/PD) models. In this study, we adapt the Eleveld model for use at deep anesthesia levels with a BSR endpoint, with the goal of aiding the estimation of the dosage of propofol needed to achieve 70-90% BSR for 15 min. We test the ability of the adapted model to predict BSR for these treatments. Twenty participants underwent 6-9 treatments of high doses of propofol (5-9 of which were included in this analysis) for a total of 115 treatments. To adapt the Eleveld model for this endpoint, we optimized the model parameters Ke0, γ and C
Identifiants
pubmed: 36967391
doi: 10.1007/s10877-023-00986-7
pii: 10.1007/s10877-023-00986-7
doi:
Substances chimiques
Propofol
YI7VU623SF
Anesthetics, Intravenous
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1369-1377Subventions
Organisme : Center for Clinical and Translational Science, University of Utah
ID : UL1TR002538
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–34. https://doi.org/10.2147/NDT.S198774 .
doi: 10.2147/NDT.S198774
pubmed: 32021216
pmcid: 6982454
Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, Boland E, Weber RP, Randolph C, Bann C, Coker-Schwimmer E, Viswanathan M, Lohr KN. Defining treatment-resistant depression. Depress Anxiety. 2019;37(2):134–45. https://doi.org/10.1002/da.22968 .
doi: 10.1002/da.22968
pubmed: 31638723
Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. https://doi.org/10.4088/JCP.20m13699 .
doi: 10.4088/JCP.20m13699
pubmed: 33989464
Tadler SC, Mickey BJ. Emerging evidence for antidepressant actions of anesthetic agents. Curr Opin Anaesthesiol. 2018;31(4):439–45. https://doi.org/10.1097/ACO.0000000000000617 .
doi: 10.1097/ACO.0000000000000617
pubmed: 29794854
Langer G, Karazman R, Neumark J, Saletu B, Schönbeck G, Grünberger J, Dittrich R, Petricek W, Hoffmann P, Linzmayer L, Anderer P, Steinberger K. Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. Neuropsychobiology. 1995;31(4):182–94. https://doi.org/10.1159/000119190 .
doi: 10.1159/000119190
pubmed: 7659199
Weeks HRIII, Tadler SC, Smith KW, Iacob E, Saccoman M, White AT, Landvatter JD, Chelune GJ, Suchy Y, Clark E, Cahalan MK, Bushnell L, Sakata D, Light AR, Light KC. Antidepressant and neurocognitive effects of isoflurane anesthesia versus electroconvulsive therapy in refractory depression. PLoS ONE. 2013;8(7):e69809. https://doi.org/10.1371/journal.pone.0069809 .
doi: 10.1371/journal.pone.0069809
pubmed: 23922809
pmcid: 3724904
Mickey BJ, White AT, Arp AM, Leonardi K, Torres MM, Larson AL, Odell DH, Whittingham SA, Beck MM, Jessop JE, Sakata DJ, Bushnell LA, Pierson MD, Solzbacher D, Kendrick EJ, Weeks HR III, Light AR, Light KC, Tadler SC. Propofol for treatment-resistant depression: a pilot study. Int J Neuropsychopharmacol. 2018;21(12):1079–89. https://doi.org/10.1093/ijnp/pyy085 .
doi: 10.1093/ijnp/pyy085
pubmed: 30260415
pmcid: 6276046
Brown PL, Zanos P, Wang L, Elmer GI, Gould TD, Shepard PD. Isoflurane but not halothane prevents and reverses helpless behavior: a role for EEG burst suppression? Int J Neuropsychopharmacol. 2018;21(8):777–85. https://doi.org/10.1093/ijnp/pyy029 .
doi: 10.1093/ijnp/pyy029
pubmed: 29554264
pmcid: 6070045
Greenberg LB, Gage J, Vitkun S, Fink M. Isoflurane anesthesia therapy: a replacement for ECT in depressive disorders? Convuls Ther. 1987;3(4):269–77.
pubmed: 11940928
Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer SL. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic– pharmacodynamic model. Anesthesiology. 2001;95(2):324–33. https://doi.org/10.1097/00000542-200108000-00011 .
doi: 10.1097/00000542-200108000-00011
pubmed: 11506101
Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation. Br J Anaesth. 2018;120(5):942–59. https://doi.org/10.1016/j.bja.2018.01.018 .
doi: 10.1016/j.bja.2018.01.018
pubmed: 29661412
Vellinga R, Hannivoort LN, Introna M, Touw DJ, Absalom AR, Eleveld DJ, Struys MMRF. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia. Br J Anaesth. 2021;126(2):386–94. https://doi.org/10.1016/j.bja.2020.10.027 .
doi: 10.1016/j.bja.2020.10.027
pubmed: 33317804
Bruhn J, Bouillon TW, Shafer SL. Bispectral Index (BIS) and burst suppression: revealing a part of the BIS algorithm. J Clin Monit Comput. 2000;16(8):593–6. https://doi.org/10.1023/A:1012216600170 .
doi: 10.1023/A:1012216600170
pubmed: 12580235
Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008;22(6):633–48. https://doi.org/10.1111/j.1472-8206.2008.00633.x .
doi: 10.1111/j.1472-8206.2008.00633.x
pubmed: 19049668
Absalom AR, Mani V, De Smet T, Struys MMRF. Pharmacokinetic models for propofol—defining and illuminating the devil in the detail. Br J Anaesth. 2009;103(1):26–37. https://doi.org/10.1093/bja/aep143 .
doi: 10.1093/bja/aep143
pubmed: 19520702
Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm. 1992;20(1):63–94. https://doi.org/10.1007/BF01143186 .
doi: 10.1007/BF01143186
pubmed: 1588504
Adler AC. Propofol: review of potential risks during administration. AANA J. 2017;85(2):104–7.
pubmed: 30501158
Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122(4):448–59. https://doi.org/10.1016/j.bja.2018.12.025 .
doi: 10.1016/j.bja.2018.12.025
pubmed: 30857601
pmcid: 6435842